Allergy

Early allergen introduction, microbiome research, and immune programming studies suggest food allergy prevention may begin during infancy.

Engel discusses ADAA 2026 findings identifying fear of social judgment as a distinct component of food allergy–related anxiety in adolescents.

Stay updated with the latest healthcare breakthroughs, including FDA actions, in this week’s essential news roundup.

Chase discusses how the FDA’s labeling change aligns epinephrine nasal spray (neffy) with other weight-based epinephrine formulations.

Chase explains how the weight-based labeling update for epinephrine nasal spray (neffy) may improve access, adherence, and real-world use in young children.

FDA approvals, new HAE guidance, epinephrine access shifts, and phase 3 peanut patch data defined major allergy developments across Q1 2026.

March 2026 allergy news: FDA label updates, mastocytosis NDA, and promising data for peanut patch, remibrutinib, and CRSwNP biologics.

A study shows that weekly or daily throat clearing, hoarseness, and voice strain are more common among those with diagnosed respiratory allergies, particularly among women.

The FDA has approved a labeling update for 1 mg epinephrine nasal spray permitting use in any patient weighing 33 lbs or more.

Population study links respiratory allergies to hoarseness, throat clearing, and vocal fatigue, with greater symptom burden in women and unified airway implications.

New research identifies dietary epitopes driving oral tolerance, offering insight into Treg responses, early exposure, and future food allergy therapies.

Su emphasized how care should be shifted to reflect known impacts of NNAALs on obstetric care.

Angkeow discusses a recent study finding that PhIP-Seq analysis links diverse IgG responses to food allergy phenotypes.

Su discussed the role of delabeling non-narcotic analgesic allergy labels in obstetrics care.

In this Q&A, Fleischer discusses clinically meaningful gains in peanut allergy desensitization, strong response rates, and the path toward FDA submission for VP250.

Phase 3 VITESSE data show VIASKIN peanut patch improves tolerance in most children, with high adherence and a favorable safety profile.

Shamji shared the factors influencing which treatments are best for each patient and further research he'd like to see.

Su described how NNAALs drive management decisions in pregnancy and post partum care.

High costs, limited insurance coverage, and adherence challenges remain key barriers to broader SLIT use in the US, Larenas-Linnemann says in an interview at AAAAI 2026.

Investigational RNA interference therapy targeting prekallikrein enters accelerated regulatory pathway as phase 2 trial evaluates long-acting prophylaxis for HAE.

The FDA has set a PDUFA date of December 30, 2026.

At AAAAI 2026, Anna Nowak-Wegrzyn, MD, discussed the use of ondansetron, home management strategies, and guidance on the gradual reintroduction of foods in FPIES.

Research presented at AAAAI 2026 found that 88% of participants preferred intranasal epinephrine over injectables.

Data presented at AAAAI 2026 showed that adding dupilumab to omalizumab-facilitated oral immunotherapy improved desensitization and reduced gastrointestinal adverse events.